(Reuters) – The U.S. Food and Drug Administration said on Thursday it plans to replace animal testing in the development of monoclonal antibody therapies and other drugs with “human-relevant methods,” including the use of AI-based models.
(Reporting by Mariam Sunny in Bengaluru; Editing by Alan Barona)
Comments